Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM17 in Chinese Healthy Participants
NCT07466940Phase 1Completed
- Sponsor
- SinoMab BioScience Limited
- Start
- Oct 2025
- Primary completion
- Feb 2026
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SM17 in atopic dermatitis (AD), asthma and inflammatory bowel disease (IBD) (4 cohorts), sponsored by SinoMab BioScience Limited. Primary endpoint: Incidence of treatment emergent adverse events. Started Oct 2025; status: completed.
02
Drugs
SM17
03
Conditions
atopic dermatitis (AD)asthmainflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07466940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07466940.